Periapical Healing Following Endodontic Treatment in Patients Receiving Bisphosphonates: Implications for Medication-related Osteonecrosis of the Jaw
Year: 2026
Type: article
Abstract: Background Medication-related osteonecrosis of the jaw (MRONJ) is a clinically important complication associated with antiresorptive therapy, particularly bisphosphonates. Tooth extraction is a major local risk factor, while persistent odontogenic infection and apical periodontitis may also contribute to local conditions associated with MRONJ. Aims This narrative review aimed to evaluate evidence on periapical healing after endodontic treatment in patients receiving bisphosphonates and to clarify the potential relevance of infection control and tooth preservation to MRONJ risk management. Materials and Methods A narrative literature review was performed. PubMed, Scopus, and Google Scholar were searched for English-language publications published from 2003 to 14 July 2026 concerning bisphosphonates, MRONJ, apical periodontitis, periapical healing, and endodontic treatment outcomes. Evidence was summarized thematically. Results Forty-one publications were included, but only a small number directly evaluated endodontic outcomes in patients receiving bisphosphonates. Available evidence suggests that satisfactory periapical healing and tooth retention can be achieved, particularly in patients treated for osteoporosis, whereas outcomes may be less predictable during prolonged intravenous zoledronate therapy. Apical periodontitis and chronic odontogenic infection may sustain local inflammation relevant to MRONJ, but their causal role remains unproven. Conclusions Non-surgical root canal treatment may be a reasonable tooth-preserving option when the tooth is restorable and predictable infection control can be achieved. However, current evidence does not demonstrate that endodontic treatment prevents MRONJ. Clinical decisions should distinguish patients with osteoporosis receiving oral bisphosphonates from oncology patients receiving prolonged intravenous therapy and should be individualized according to the patient’s overall MRONJ risk.
Source: Archiv Euromedica
Language: English
Topic: Bone health and treatments
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7204752927
